Oxford Asset Management’s Arbutus Biopharma ABUS Stock Holding History

Oxford Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-21,632	Closed	-$104K	–	445
2025 Q4	$104K	Buy	+21,632	New	+$97.3K	0.04%	445
2025 Q3	–	Sell	-12,143	Closed	-$37.5K	–	432
2025 Q2	$37.5K	Buy	+12,143	New	+$40.3K	0.01%	505
2020 Q1	–	Sell	-22,051	Closed	-$61K	–	213
2019 Q4	$61K	Buy	+22,051	New	+$35.7K	﹤0.01%	1658
2019 Q2	–	Sell	-71,560	Closed	-$256K	–	1665
2019 Q1	$256K	Buy	71,560 +29,517	+70%	+$113K	0.01%	1448
2018 Q4	$161K	Buy	42,043 +10,305	+32%	+$50.8K	﹤0.01%	1584
2018 Q3	$302K	Sell	31,738 -179,377	-85%	-$1.78M	0.01%	1492
2018 Q2	$1.54M	Sell	211,115 -42,631	-17%	-$254K	0.03%	817
2018 Q1	$1.27M	Sell	253,746 -88,007	-26%	-$466K	0.03%	815
2017 Q4	$1.74M	Buy	341,753 +217,480	+175%	+$1.27M	0.04%	648
2017 Q3	$778K	Buy	124,273 +40,963	+49%	+$175K	0.02%	1050
2017 Q2	$300K	Buy	83,310 +39,436	+90%	+$136K	0.01%	1258
2017 Q1	$143K	Sell	43,874 -116,312	-73%	-$323K	﹤0.01%	1343
2016 Q4	$392K	Buy	+160,186	New	+$466K	0.01%	626

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Oxford Asset Management's ABUS Position: Q1 2026 in Review

Oxford Asset Management sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 21,632 shares — an estimated $104K sold.

Oxford Asset Management first reported a position in ABUS in Q4 2016 and held it in 13 quarters. The position peaked at $1.74M in Q4 2017. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

Oxford Asset Management reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
Oxford Asset Management sold 21,632 Arbutus Biopharma shares in Q1 2026, an estimated $104K.
Oxford Asset Management first reported a position in Arbutus Biopharma in Q4 2016 and held it in 13 quarters.
Oxford Asset Management's Arbutus Biopharma position peaked at $1.74M in Q4 2017.
167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Oxford Asset Management's 13F filing for Q1 2026, filed 15 May 2026.